Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo. Whil… [+2918 chars]
No comments yet. Be the first to comment!